$19.44 Million in Sales Expected for Oxford Immunotec Global PLC (NASDAQ:OXFD) This Quarter

Equities research analysts predict that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce sales of $19.44 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Oxford Immunotec Global’s earnings. The lowest sales estimate is $19.18 million and the highest is $19.93 million. Oxford Immunotec Global reported sales of $29.32 million during the same quarter last year, which indicates a negative year over year growth rate of 33.7%. The business is scheduled to issue its next earnings report on Tuesday, July 30th.

According to Zacks, analysts expect that Oxford Immunotec Global will report full year sales of $70.41 million for the current financial year, with estimates ranging from $70.16 million to $70.58 million. For the next fiscal year, analysts anticipate that the business will report sales of $81.49 million, with estimates ranging from $79.32 million to $82.86 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.14. The business had revenue of $14.79 million for the quarter, compared to the consensus estimate of $13.74 million. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The firm’s quarterly revenue was up 26.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.40) earnings per share.

Several research firms have recently weighed in on OXFD. BidaskClub downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Zacks Investment Research downgraded shares of HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. TheStreet downgraded shares of Viavi Solutions from a “b-” rating to a “c+” rating in a research report on Monday, June 3rd. Finally, ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Oxford Immunotec Global presently has an average rating of “Hold” and a consensus price target of $18.00.

In related news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $16.05, for a total transaction of $48,150.00. Following the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $48,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.21% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of OXFD. FIL Ltd acquired a new stake in Oxford Immunotec Global in the first quarter valued at approximately $5,586,000. Martingale Asset Management L P acquired a new stake in shares of Oxford Immunotec Global in the fourth quarter worth $1,499,000. EAM Global Investors LLC acquired a new stake in shares of Oxford Immunotec Global in the first quarter worth $1,330,000. Marshall Wace LLP acquired a new stake in shares of Oxford Immunotec Global in the first quarter worth $1,185,000. Finally, Granite Investment Partners LLC acquired a new stake in shares of Oxford Immunotec Global in the first quarter worth $1,174,000. Hedge funds and other institutional investors own 91.57% of the company’s stock.

Shares of Oxford Immunotec Global stock traded down $0.16 during trading on Friday, hitting $13.31. The stock had a trading volume of 95,796 shares, compared to its average volume of 360,149. The stock’s 50 day simple moving average is $14.19. The stock has a market cap of $358.61 million, a P/E ratio of 26.10 and a beta of 0.35. The company has a quick ratio of 12.03, a current ratio of 12.60 and a debt-to-equity ratio of 0.04. Oxford Immunotec Global has a 1 year low of $11.66 and a 1 year high of $19.19.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.